Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics

The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast revenues of $2.77 billion, representing an increase of 10% year over year.Over the last 30 days, there has been a downward revision of 2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the co ...